StockNews.com Begins Coverage on Aeterna Zentaris (NASDAQ:AEZS)

StockNews.com started coverage on shares of Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) in a research note issued to investors on Wednesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Aeterna Zentaris Trading Up 0.8 %

Shares of Aeterna Zentaris stock traded up $0.02 on Wednesday, reaching $2.45. 3,285 shares of the company were exchanged, compared to its average volume of 7,305. The company has a market capitalization of $4.39 million, a price-to-earnings ratio of -0.16 and a beta of 1.55. Aeterna Zentaris has a one year low of $3.96 and a one year high of $12.00. The company has a 50-day moving average of $2.88 and a 200 day moving average of $3.13.

About Aeterna Zentaris

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.